Overview

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Status:
Terminated
Trial end date:
2019-01-17
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).
Phase:
Phase 2
Details
Lead Sponsor:
Axovant Sciences Ltd.